IPF: New insight in diagnosis and prognosis

Respiratory Medicine

Volumn 104, Issue SUPPL. 1, 2010, Pages

  Caminati, Antonella ^a   Harari, Sergio ^a  

^a San Giuseppe Hospital   (Italy)

Author keywords

Idiopathic pulmonary fibrosis; Prognostic factors; Usual interstitial pneumonia

Indexed keywords

CARBON MONOXIDE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D;

AGE; ARTICLE; DIAGNOSTIC VALUE; DISEASE EXACERBATION; DISEASE SEVERITY; EXERCISE TEST; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; NEUTROPHIL COUNT; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL TIME; THORAX RADIOGRAPHY;

DISEASE PROGRESSION; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; MALE; PREVALENCE; PROGNOSIS; SPIROMETRY; SURVIVAL ANALYSIS;

EID: 77953029679     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.03.012     Document Type: Article

References (105)

1. American Thoracic Society, and European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002) 277-304
2. Harari S., and Caminati A. Idiopathic pulmonary fibrosis. Allergy 60 (2005) 421-435
3. Wells A.U., and Hogaboam C.M. Update in diffuse parenchimal lung disease 2006. Am J Respir Crit Care Med 175 (2007) 655-660
4. Raghu G., Weycker D., Edelsberg J., Bradford W.Z., and Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174 (2006) 810-816
5. Hunninghake G., Zimmerman M.B., Schwartz D.A., King Jr. T.E., Lynch J., Hegele R., et al. Utility of lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164 (2001) 193-196
6. Strieter R.M. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 128 (2005) 526-532
7. Martinez F.J., Safrin S., Weycker D., Starko K.M., Bradford W.Z., King Jr. T.E., et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142 (2005) 963-967
8. Collard H.R., Moore B.B., Flaherty K.R., Brown K.K., Kaner R.J., King Jr. T.E., et al. Acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007) 636-643
9. Noth I., and Martinez F.J. Recent advances in idiopathic pulmonary fibrosis. Chest 132 (2007) 637-650
10. King Jr. T.E., Schwarz M.I., Brown K., Tooze J.A., Colby T.V., Waldron Jr. J.A., et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164 (2001) 1025-1032
11. Mogulkoc N., Brutsche M.H., Bishop P.W., Greaves S.M., Horrocks A.W., and Egan J.J. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 164 (2001) 103-108
12. Flaherty K.R., Mumford J.A., Murray S., Kazerooni E.A., Gross B.H., Colby T.V., et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168 (2003) 543-548
13. Collard H.R., King Jr. T.E., Bartelson B.B., Vourlekis J.S., Schwarz M.I., and Brown K.K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168 (2003) 538-542
14. Latsi P.I., du Bois R.M., Nicholson A.G., Colby T.V., Bisirtzoglou D., Nikolakopoulou A., et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168 (2003) 531-537
15. Du Bois R., and King Jr. T.E. Challenges in pulmonary fibrosis -5: the NSIP/UIP debate. Thorax 62 (2007) 1008-1012
16. Katzenstein A.L.A., and Myers J.L. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157 (1998) 1301-1315
17. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161 (2000) 646-664
18. Travis W.D., Matsui K., Moss J., and Ferrans V.J. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 24 (2000) 19-33
19. Nicholson A.G., Colby T.V., du Bois R.M., Hansell D.M., and Wells A.U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162 (2000) 2213-2217
20. Park J.H., Kim D.S., Park I.N., Jang S.J., Kitaichi M., Nicholson A.G., et al. Prognosis of fibrotic interstitial pneumonia. Idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175 (2007) 705-711
21. Bjoraker J.A., Ryu J.H., Edwin M.K., Myers J.L., and Tazelaar H.D. Prognostic significance of histopathological subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157 (1998) 199-203
22. Flaherty K.R., Travis W.D., Colby T.V., Toews G.B., Kazerooni E.A., Gross B.H., et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164 (2001) 1722-1727
23. Flaherty K.R., Toews G., Travis W.D., Colby T.V., Kazerooni E.A., Gross B.H., et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19 (2002) 275-283
24. Caminati A., and Harari S. Which prognostic indicator should we use for clinical practice in the initial evaluation and follow-up of IIP: should we depend on PFT, HRCT or. what?. Sarcoidosis Vasc Diffuse Lung Dis 22 (2005) S24-S30
25. Daniil Z.D., Gilchrist F.C., Nicholson A.G., Hansell D.M., Harris J., Colby T.V., et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 160 (1999) 899-905
26. Katzenstein A.L., and Fiorelli R.F. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am J Surg Pathol 18 (1994) 136-147
27. Travis W.D., Hunninghake G., King Jr. T.E., Lynch D.A., Colby T.V., Galvin J.R., et al. Idiopathic non specific interstitial pneumonia. Report of an American Thoracic Society project. Am J Respir Crit Care Med 177 (2008) 1338-1347
28. Nicholson A.G., and Wells A.U. Nonspecific interstitial pneumonia-nobody said it's perfect. Am J Respir Crit Care Med 164 (2001) 1553-1554
29. Monaghan H., Wells A.U., Colby T.V., du Bois R.M., Hansell D.M., and Nicholson A.G. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 125 (2004) 522-526
30. Katzenstein A.L., Zisman D.A., Litzky L.A., Nguyen B.T., and Kotloff R.M. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 26 (2002) 1567-1577
31. Nicholson A.G., Fulford L.G., Colby T.V., du Bois R.M., Hansell D.M., and Wells A.U. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 166 (2002) 173-177
32. Enomoto N., Suda T., Kato M., Kaida Y., Nakamura Y., Imokawa S., et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest 130 (2006) 22-29
33. Tiitto L., Bloigu R., Heiskanen U., Paakko P., Kinnula V.L., and Kaarteenaho-Wiik R. Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 61 (2006) 1091-1095
34. Cool C.D., Groshong S.D., Rai P.R., Henson P.M., Stewart J.S., and Brown K.K. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 174 (2006) 654-658
35. Khoshnevis M.R. Histopathology and prediction of survival in usual interstitial pneumonia. Am J Respir Crit Care Med 165 (2002) 1451-1452
36. Hunninghake G.W., Lynch D.A., Galvin J.R., Gross B.H., Müller N., Schwartz D.A., et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 124 (2003) 1215-1223
37. Souza C.A., Müller N.L., Flint J., Wright J.L., and Churg A. Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. AJR Am J Roentgenol 185 (2005) 1531-1539
38. Gotway M.B., Freemer M.M., and King Jr. T.E. Challenges in pulmonary fibrosis- 1: use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax 62 (2007) 546-553
39. Müller N.L., Miller R.R., Webb W.R., Evans K.G., and Ostrow D.N. Fibrosing alveolitis: CT - pathologic correlation. Radiology 160 (1986) 585-588
40. Nishimura K., Kitaichi M., Izumi T., Nagai S., Kanaoka M., and Itoh H. Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology 182 (1992) 337-342
41. Akira M., Sakatani M., and Ueda E. Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT. Radiology 189 (1993) 687-691
42. Flaherty K.R., Thwaite E.L., Kazerooni E.A., Gross B.H., Toews G.B., Colby T.V., et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 58 (2003) 143-148
43. Martinez F.J. Idiopathic interstitial pneumonias: usual interstitial pneumonia versus nonspecific interstitial pneumonia. Proc Am Thorac Soc 3 (2006) 81-95
44. Park I.N., Jegal Y., Kim D.S., Do K.H., Yoo B., Shim T.S., et al. Clinical course and lung function changes of idiopathic nonspecific interstitial pneumonia. Eur Respir J 33 (2009) 68-76
45. Sumikawa H., Johkoh T., Colby T.V., Ichikado K., Suga M., Taniguchi H., et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 177 (2008) 433-439
46. Flaherty K.R. High resolution computed tomography and the many faces of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177 (2008) 367-368
47. Lynch D.A., David Godwin J., Safrin S., Starko K., Hormel P., Brown K., et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 172 (2005) 488-493
48. Uppaluri R., Hoffman E., Sonka M., Hartley P., Hunninghake G., and McLennan G. Computed recognition of regional lung disease patterns. Am J Respir Crit Care Med 160 (1999) 648-654
49. Uppaluri R., Hoffman E., Sonka M., Hunninghake G., and McLennan G. Interstitial lung disease: a quantitative study using the adaptive multiple feature method. Am J Respir Crit Care Med 159 (1999) 519-525
50. King Jr. T.E., Tooze J.A., Schwarz M.I., Brown K.R., and Cherniack R.M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164 (2001) 1171-1181
51. Hubbard R., Johnston I., and Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 113 (1998) 396-400
52. Erbes R., Schaber T., and Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome?. Chest 111 (1997) 51-57
53. Schwartz D.A., Helmers R.A., Galvin J.R., Van Fossen D.S., Frees K.L., Dayton C.S., et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 149 (1994) 450-454
54. Schwartz D.A., Van Fossen D., Davis C.S., Helmers R.A., Dayton C.S., Burmeister L.F., et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 149 (1994) 444-449
55. King Jr. T.E., Safrin S., Starko K., Brown K., Noble P., Raghu G., and Schwartz D. Analyses of efficacy end points in a controlled trial of interferon-1b for idiopathic pulmonary fibrosis. Chest 127 (2005) 171-177
56. Jegal U., Kim D., Shim T., Lim C., Lee S., Koh Y., et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171 (2005) 639-644
57. Egan J., Martinez F., Wells A., and Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 60 (2005) 270-273
58. Martinez F.J., and Flaherty K.R. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 3 (2006) 315-321
59. Wells A., Rubens M., du Bois R., and Hansell D. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol 161 (1993) 1159-1165
60. Gay S.E., Kazerooni E.A., and Toews G.B. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 157 (1998) 1063-1072
61. Raghu G., Brown K.K., Bradford W.Z., Starko K., Noble P.W., Schwartz D.A., et al. Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2004) 125-133
62. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H.M., et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353 (2005) 2229-2242
63. Raghu G., Brown K.K., Costabel U., Cottin V., du Bois R.M., Lasky J.A., et al. Treatment of idiopathic pulmonary fibrosis with etanercept. An exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178 (2008) 948-955
64. King Jr. T.E., Albera C., Bradford W.Z., Costabel U., Hormel P., Lancaster L., et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374 (2009) 222-228
65. King Jr. T.E., Behr J., Brown K.K., du Bois R.M., Lancaster L., de Andrade J.A., et al. BUILD1: a randomised placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177 (2008) 75-81
66. Watters L., King T., Schwarz M., Waldron J., and Stanford R. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 133 (1986) 97-103
67. Watters L., Schwarz M., Cherniack R., Waldron J.A., Dunn T.L., Stanford R.E., et al. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 135 (1987) 696-704
68. Hansen J.E., and Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 109 (1996) 1566-1576
69. Lama V.N., and Martinez F.J. Resting and exercise physiology in interstitial lung diseases. Clin Chest Med 25 (2004) 435-453
70. Eaton T., Young P., Milne D., and Wells A.U. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171 (2005) 1150-1157
71. American Thoracic Society/American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167 (2003) 211-277
72. Fell C.D., Liu L.X., Motika C., Kazerooni E.A., Gross B.H., Travis W.D., et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179 (2009) 402-407
73. Lama V.N., Flaherty K.R., Toews G.B., Colby T.V., Travis W.D., Long Q., et al. Prognostic value of desaturation during a six-minute-walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168 (2003) 1084-1090
74. Hallstrand T.S., Boitano L.J., Johnson W.C., Spada C.A., Hayes J.G., and Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 25 (2005) 96-103
75. Lederer D.J., Arcasoy S.M., Wilt J.S., D'Ovidio F., Sonett J.R., and Kawut S.M. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174 (2006) 659-664
76. Caminati A., Bianchi A., Cassandro R., Mirenda M.R., and Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic interstitial fibrosis. Respir Med 103 (2009) 117-123
77. Flaherty K.R., Andrei A.-C., Murray S., Fraley C., Colby T.V., Travis W.D., et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six minute hallwalk. Am J Resp Crit Care Med 174 (2006) 803-809
78. Kim D.S., Collard H.R., and King Jr. T.E. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3 (2006) 285-292
79. Azuma A., Nukiwa T., Tsuboi E., Suga M., Abe S., Nakata K., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040-1047
80. Kubo H., Nakayama K., Yanai M., Suzuki T., Yamaya M., Watanabe M., et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128 (2005) 1475-1482
81. Kim D.S., Park J.H., Park B.K., Lee J.S., Nicholson A.G., and Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 27 (2006) 143-150
82. Parambil J.G., Myers J.L., and Ryu J.H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 128 (2005) 3310-3315
83. Akira M., Hamada H., Sakatani M., Kabayashi C., Nishioka M., and Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 168 (1997) 79-83
84. Ambrosini V., Cancellieri A., Chilosi M., Zompatori M., Trisolini R., Saragoni L., et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 22 (2003) 821-826
85. Churg A., Muller N.L., Silva I.S., and Wright J.L. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol 31 (2007) 277-284
86. Agarwal R., and Jindal S.K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 19 (2008) 227-235
87. Akira M., Kozuka T., Yamamoto S., and Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 178 (2008) 372-378
88. Akira M. Computed tomography and pathologic findings in fulminant forms of idiopathic interstitial pneumonia. J Thorac Imaging 14 (1999) 76-84
89. Homma S., Sakamoto S., Kawabata M., Kishi K., Tsuboi E., Motoi N., et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 44 (2005) 1144-1150
90. Lettieri C.J., Nathan S.D., Barnett S.D., Ahmad S., and Shorr A.F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129 (2006) 746-752
91. Nathan S.D., Noble P.W., and Tuder R.M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 175 (2007) 875-880
92. Nadrous H.F., Pellikka P.A., Krowka M.J., Swanson K.L., Chaowalit N., Decker P.A., et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128 (2005) 2393-2399
93. Nathan S.D., Shlobin O.A., Ahmad S., Urbanek S., and Barnett S.D. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131 (2007) 657-663
94. Lederer D.J., Caplan-Shaw C.E., O'Shea M.K., Wilt J.S., Basner R.C., Bartels M.N., et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 6 (2006) 398-403
95. Kinder B.W., and Wells A.U. The art and science of diagnosing interstitial lung diseases. Am J Respir Crit Care Med 179 (2009) 974-975
96. Peikert T., Daniels C.E., Beebe T.J., Meyer K.C., and Ryu J.H. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med 102 (2008) 1342-1348
97. Kinder B.W., Brown K.K., Schwarz M.I., Ix J.H., Kervitsky A., and King Jr. T.E. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 133 (2008) 226-232
98. Veeraraghavan S., Latsi P.I., Wells A.U., Pantelidis P., Nicholson A.G., Colby T.V., et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 22 (2003) 239-244
99. Tabuena R.P., Nagai S., Tsutsumi T., Handa T., Minoru T., Mikuniya T., et al. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration 72 (2005) 490-498
100. Greene K.E., Wright J.R., Steinberg K.P., Ruzinski J.T., Caldwell E., Wong W.B., et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 160 (1999) 1843-1850
101. Greene K.E., Ye S., Mason R.J., and Parsons P.E. Serum surfactant protein-A levels predict development of ARDS in at-risk patients. Chest 116 (1999) 90S-91S
102. McCormack F.X., King Jr. T.E., Bucher B.L., Nielsen L., and Mason R.J. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 152 (1995) 751-759
103. Phelps D.S., Umstead T.M., Mejia M., Carrillo G., Pardo A., and Selman M. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest 125 (2004) 617-625
104. Kinder B.W., Brown K.K., McCormack F.X., Ix J.H., Kervitsky A., Schwarz M.I., et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 135 (2009) 1557-1563
105. Hyzy R., Huang S., Myers J., Flaherty K., and Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132 (2007) 1652-1658